RxDoctor Payments Data

Judita Slusnys

Family · Palos Heights, ILNPI 1770956476

Payments from drug & device makers

$7,127in general payments, 2019–2025

Across 364 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Electromed, Inc.$692
  • Jazz Pharmaceuticals Inc.$461
  • Grifols USA, LLC$361
  • Boehringer Ingelheim$321
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$7,04899%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,127 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$2,677
Medicare patients
22
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter109$132,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$30,585
Spiriva RespimatTiotropium Bromide15$16,574
SymbicortBudesonide/Formoterol Fumarate12$6,626
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$4,027
Albuterol Sulfate HfaAlbuterol Sulfate100$3,983
Advair HfaFluticasone Propion/Salmeterol11$3,642
Ventolin HfaAlbuterol Sulfate17$2,817
Montelukast Sodium71$666
Fluticasone Propionate28$629
Clotrimazole29$458
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate13$365
Pantoprazole Sodium12$228
Methylprednisolone28$222
Azithromycin31$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$1,407$132,026109 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,990$37,21138 claims
Boehringer IngelheimSpiriva Respimat$321$16,57415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →